THE PATENTS, companion pdf for the video
Kathleen Dickson
The “Lyme Disease” Patents
– the research fraud and
racketeering complaint data for the USDOJ to prosecute; This video teaches you
how to use the patent databases to search for related conflict of interest or
racketeering data. In the patents you
will find all sorts of language contradictory to what the Lyme cabal or IDSA,
now, uses publicly. Therefore, these patents MUST all be studied and examined
by you. These are legal patent CLAIMS
and therefore, for the most part, truthful.
These individuals can’t very well patent a non-truth or someone else
will patent the actual truth, useful for scientific history as well as
commercially.
VID10 THE LYME CRYME PATENTS (Feb 15, 2015)
https://www.youtube.com/watch?v=XQB0VFZiKxg
This document is a companion (to the video) list of CDC officers and
ALDF.com/Yale/NYMC associates who own patents related to Lyme and other TBDs;
the Dearborn event was not only research fraud but interest-conflicted, as were
the FDA panels to approve LYMErix (they were all the same characters: Steere,
Barbour, Schoen, Rahn, Johnson, Weinstein, McSweegan, etc).
=====
A little background about this Dearborn/OspA-scam, since it
is the central or essence of the crimes:
“Dearborn” refers to the 1994 CDC conference (took place in Dearborn,
MI) where the testing for Lyme was falsified, or changed from that which
represented the Lyme spirochete as just
another relapsing fever organism,… to something else entirely contrived (not
even empirically perceived) and false.
That event is discussed in this video and the other ones in the YouTube
series called “Lyme Crymes.”
For years, no one among this CDC/ALDF/Yale.NYMC cabal would admit that rOspA
(recombinant outer surface protein A of the Borrelia burgdorferi organism or
the Lyme vaccines that came and went) was Pam3Cys, because they couldn’t. If they said “OspA is Pam3Cys,” everyone
would know from officialdom that it was never a vaccine and the ALDF.com’s (now
IDSA’s) whole house of cards would
collapse. rOspA is a fungal antigen that causes immunosuppression – the
opposite of a “vaccine.” If OspA was
not a vaccine, then the CDC’s 1994 “Dearborn” 2-tiered testing schema was a
lie.
The falsified Dearborn case definition was the lie invented to pass off bogus
OspA vaccines. You can tell for sure
because they left OspA and B out (A and B are encoded on the same plasmid so
you can’t leave out one without the other) of the diagnostic standard. One never tests for vaccine efficacy with the
same antigen that is the vaccine.
For example, if I made a recombinant measles vaccine based on a DNA sequence
that coded for say, “XYZ” surface antigen, I would not use recombinant “XYZ”
surface antigen in the testing schema to see if a person had measles because I
would not know if the antibody band was from the organism or the vaccine.
It was known at least since the late 1980s that people with late neurologic
Lyme disease ceased to produce antibodies.
However, the Dearborn case definition (Steere, that is) rejected those classes of disease – early
and late meningitis or chronic neurologic cases - and said instead that only
the blatantly, highly immunoreactive class of Lyme victims, those with the
HLA-linked or arthritis-linked or hypersensitivity-linked cases, or those who
produced abundant IgG antibodies could be called a “case” of “Lyme
Disease.” This falsification of the
testing was as much a semantics game was it was straight up research fraud from
these DNA patenteers. This Dearborn
event left the sickest people with no disease diagnosis.
If I intended a monopoly on a new diseases set or an entirely new class of
diseases, such as what African vector
borne diseases arriving in North America were discovered to be, what would I
do? I’d make sure I got all of it:
vaccines, test kits, grants, funding, all future blood testing for all future
potentially patentable goodies in that blood, publicity, my name on plaques and
statues (like Alan Barbour), awards like an “Astute Clinician Award,”… or, I
could be knighted like Simon Wessely, a psychiatrist who helps by calling all
the victims of the Lyme scam and Gulf War Illness “crazy” and “terrorists,” and
US States naming, like, “Allen Steere Day” after me…
The Dearborn stunt is to the present day, the lie these
criminals are trying to defend by issuing fake “guidelines” based on the
fraudulent, 2001, Klempner non-retreatment report,
Two controlled trials of antibiotic treatment in patients
with persistent symptoms and a history of Lyme disease.
http://www.ncbi.nlm.nih.gov/pubmed/11450676
and with this cabal’s chronic hystrionics over the development of other tests
for Lyme, etc., because that, Dearborn, will be the most serious criminal
charge – the homicide charge. All the
ALDF.com and DNA patent-owners, here, have slandered and libeled against Lyme
victims, making this not a simply negligent homicide charge. All of their derogatory slander and label and trash-talking Lyme and LYMErix
victims show “intent to cause harm,” which is not negligent homicide or
manslaughter, but murder and maiming.
Barbour, Alan G., CDC officer and participant in the Dearborn conference, owns
30+ patents including the ImmuLyme OspA patent. The ImmuLyme vaccine trial
report authors (Sigal, et al) and Barbour assert that one must be sure lipids
are attached to all Osps or else they will not be immunogenic, yet Steere’s
Dearborn panel was developed from high passage G39/40 and FRG with recombinant
OspA and B with no lipids attached, leaving OspA and B out of the case
definition panel.
Barbour’s ImmuLyme patent (&Berstrom, Magnarelli) European Patent #
(5092/88, DK)
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5523089.PN.&OS=PN/5523089&RS=PN/5523089
Yale’s LYMErix OspA patent (5,747,294):
http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5747294.PN.&OS=PN/5747294&RS=PN/5747294
ImmuLyme trial result (falsified; used Dearborn, blots were unreadable):
A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein
A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease
Vaccine Study Consortium.
http://www.ncbi.nlm.nih.gov/pubmed/9673299
LYMErix trial result (falsified; used Dearborn, blots were
unreadable):
Vaccination against Lyme disease with recombinant Borrelia burgdorferi
outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group.
http://www.ncbi.nlm.nih.gov/pubmed/9673298
Barbour says OspA will not work as a vaccine due to antigenic variation, 1992:
Antibody-resistant mutants of Borrelia burgdorferi: in vitro
selection and characterization.
http://www.ncbi.nlm.nih.gov/pubmed/1339462
Fikrig and Flavell say OspA will not work as a vaccine due
to “selection pressure” or antigenic variation, 1995:
Selection of
variant Borrelia burgdorferi isolates from mice immunized with outer surface
protein A or B.
http://www.ncbi.nlm.nih.gov/pubmed/7729870
1992-1994. Steere Falsifies Test in
Europe: uses “high passage strains” and “OspA and B without the lipid attached”
to leave OspA and B out of the standard for his later monopoly on vector borne
diseases testing. Only Corixa, Imugen
and Yale were to be licensed to use the RICO strain patent by Dave Persing (US
Patent # 6,045,804)
Antibody responses to the three genomic groups of Borrelia
burgdorferi in European Lyme borreliosis.
http://www.ncbi.nlm.nih.gov/pubmed/8106763
“The group 1 strain of B. burgdorferi, G39/40, used in this
study and in the previous study of US patients was isolated from an Ixodes
damini tick in Guilford, Connecticut [21]. The group 2 strain, FRG [Federal Republic of Germany], was
isolated from Ixodes ricinus near Cologne [22]. The group 3 strain,
IP3, was isolated from Ixodes persulcatus near Leningrad [23]. All three
strains used in this study were high passage isolates, which were classified by
Richard Marconi (Rocky Mountain Laboratory, Hamilton, MT) using 16S ribosomal
RNA sequence determination as described [11, 24]. The recombinant
preparations of OspA and OspB used in this study were purified maltose- binding
protein-Osp fusion proteins derived from group 1 strain B31 [25]. The
fusion proteins contained the full-length OspA or OspB sequence without the
lipid moiety or the signal sequence -"
Full Text @ http://www.actionlyme.org/STEERE_IN_EUROPE.htm
Dearborn: http://www.actionlyme.org/DEARBORN_PDF.pdf
See in the Dearborn booklet: none of the labs agreed with this Dearborn
proposal in that Dearborn pdf. (Except
MarDx Labs, which was given arthritis-positive blood to qualify their Western
Blot strips prior to Dearborn; MarDx was then was given both vaccine trial
contracts; MarDx was then sold to an company in Ireland, taking all the fraud
data with them; Trinity Biotech was the name of the company that bought MarDx).
The CDC sent labs an invitation to participate, but then CDC blew them all off:
http://www.actionlyme.org/DEARBORNINVITATION.pdf
Barbour also patented Masters’ disease or STARI while the crooks played the DNA/RNA shell game
http://www.actionlyme.org/PRIMERSHELLGAME.htm
to pull the wool over Edwin Masters’ eyes and to say “There
is no ‘Lyme’ in Missouri or the south.”
To patent a unique species, you have to patent the flagellin gene. The same should be true for diagnostics –
using unique recombinant flagellins from all Borreliae.
Telford Phylogeny with Masters’ Amblyomma Borrelia:
Lone star tick-infecting borreliae are most
closely related to the agent of bovine borreliosis.
http://www.ncbi.nlm.nih.gov/pubmed/11158095
Barbour’s Patent for Masters’ disease or something close to it [either
lonestari or barbouri; the phylogenetic data says they are the same in 16S RNA
and only slightly different in the flagellin gene (96% homology), so both
evolved from theileri, which is cow relapsing fever; one species is now called
barbouri and the other is called lonestari, but really they are Masters
disease, since he was the one who for years claimed there was a Lyme-like
illness in the south, associated with a Lyme-like rash and tick bite]:
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5,932,220.PN.&OS=PN/5,932,220&RS=PN/5,932,220
Johnson, Barbara J., CDC officer, Ft. Collins, CO., owner of
5 patents in Europe with SmithKline, talks about differences in HLAs of mice,
referring to their tendency to produce HLA-linked hypersensitivity responses or
not, meaning she is aware that the same applies to humans.
CDC’s BJ Johnson oversaw this Dearborn-Falsification-of-Lyme-Testing stunt (Oct
1994). She said to not use high passage
strains, yet high passage G39/40 and FRG (Federal Republic of Germany) were
what Steere used to develop the Dearborn panel along with recombinant OspA and
B with no lipids attached. This was
done, again, to assure OspA and B were not included in the Dearborn panel, … to
facilitate what Steere, Corixa, L2 Diagnostics and Imugen intended to do after
LYMErix was on the market, … which was to monopolize the Lyme or tick-borne
diseases testing market where “the vaccination status was unknown.” RICO patent
6.045,804]
Johnson’s Patents (5 in all):
http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=19931209&CC=WO&NR=9324145A1&KC=A1
Dearborn Booklet http://www.actionlyme.org/DEARBORN_PDF.pdf
Fikrig and Flavell – own both the only scientifically valid method to detect Lyme and also own the LYMErix OspA patent. ***Their FDA-valid flagellin method was not used to assess the outcome of LYMErix because they knew not only did LYMErix not work because Lyme is a Relapsing Fever organism and undergoes antigenic variation (OspA itself, Fikrig and Flavell said, undergoes antigenic variation or “selection pressure” and would be no good as a vaccine), but Pam3Cys or TLR2/1 agonists (OspA is Pam3Cys) are fungal and cause immunosuppression in most people – especially people without Steere’s alleged HLA-linked hypersensitivity responses.***
OspA patent
http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5747294.PN.&OS=PN/5747294&RS=PN/5747294
Fikrig and Flavell’s (Yale’s) Valid (per FDA) flagellin method patent
5,618,533:
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5,618,533.PN.&OS=PN/5,618,533&RS=PN/5,618,533
The PubMed report that goes with the Yale FDA-validated flagellin method
(detects 94.4% of all cases, including earliest and late neurologic), 1991:
Molecular characterization of the humoral
response to the 41-kilodalton flagellar antigen of Borrelia burgdorferi, the
Lyme disease agent.
http://www.ncbi.nlm.nih.gov/pubmed/1894359
Fikrig and Flavell say OspA will not work due to antigenic
variation:
Selection of
variant Borrelia burgdorferi isolates from mice immunized with outer surface
protein A or B.
http://www.ncbi.nlm.nih.gov/pubmed/7729870
Padula and OspC – says Borrelia burgdorferi strain B31 has little to no OspC in
it, meaning whoever Western Blots with this strain will be leaving OspA, B and
C out of the standard. If you have
those bands, you will be told you do not have Lyme, yet they are the “primary,
immunodominant antigens,” which was why they got the assignments A, B, C,
etc. SmithKline used this strain, B31,
to WB LYMErix victims and claimed to be using the Dearborn method to detect
Lyme or vaccine failure.
Padula OspC patent: USPatent No. 5,620,862
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5,620,862.PN.&OS=PN/5,620,862&RS=PN/5,620,862
Padula OspC – not in strain B31 PubMed report:
Molecular characterization and expression of p23 (OspC) from a North American strain of Borrelia burgdorferi.
http://www.ncbi.nlm.nih.gov/pubmed/8225587
Persing, Schoen and the RICO-within-the-RICO patent – this patent shows the intention of Steere’s Dearborn, falsified case definition (you will see later, in an announcement by the Mayo Clinic, below).
US Patent # 6,045,804
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6,045,804.PN.&OS=PN/6,045,804&RS=PN/6,045,804
This patent reveals they know LYMErix causes a systemic
disease like chronic Lyme, and in this
patent they reveal their intended monopoly on post-LYMErix testing for the USA
and Canada as they claimed in their advertising:
"Additional uncertainty may arise if the vaccines are
not completely protective; vaccinated patients with multisystem complaints
characteristic of later presentations of Lyme disease may be difficult to
distinguish from patients with vaccine failure."
"The present invention provides a method useful to detect a B. burgdorferi infection in a subject. The method provided by the invention is particularly useful to discriminate B. burgdorferi infection from OspA vaccination, although it is sufficiently sensitive and specific to use in any general Lyme disease screening or diagnostic application. Thus, the method of the invention is particularly appropriate for large scale screening or diagnostic applications where only part of the subject population has been vaccinated or where the vaccination status of the population is unknown. "
Persing and Sigal later reveal that the Western Blots in
both vaccine trials were unreadable.
Both vaccine trials used MarDx test strips and said they were using the
Dearborn method to assess the efficacies of these vaccines. Arthur Weinstein was the Data Safety Monitor
for one of those trials and was also a participant in the Dearborn scam. Obviously Weinstein never looked at any of
the data he was safety-monitoring since the Western Blots were unreadable. In reality, neither OspA vaccine trial group
could tell whether or not OspA prevented Lyme, so those vaccine trial reports
were research fraud events and reports.
This Persing-Schoen RICO-RICO Patent 6,045,804, is also written up this PubMed
report, co-written by Yale’s Robert Schoen:
Borrelia burgdorferi enzyme-linked immunosorbent assay for
discrimination of OspA vaccination from spirochete infection.
http://www.ncbi.nlm.nih.gov/pubmed/8968914
Dattwyler, Raymond J. - owns a patent that describes OspA as
Pam3Cys. Therefore it could not have been a blood-stream-injected
“vaccine,” because it is a human TLR2/1 agonist. This Dattwyler patent is for an inhalation form of
OspA/Pam3Cys. Lung immunity is
different from injecting fungal antigens directly into the blood stream:
(US20090324638) LIVE BACTERIAL VACCINE
"A lipidation/processing reaction has been described for the intact OspA gene of B. burgdorferi. The primary translation product of the full-length B. burgdorferi OspA gene contains a hydrophobic N-terminal sequence, of 16 amino acids, which is a substrate for the attachment of a diacyl glyceryl to the sulflhydryl side chain of the adjacent cysteine (Cys) residue (at position 17). Following this attachment, cleavage by signal peptidase II and the attachment of a third fatty acid to the N-terminus occurs. The completed lipid moiety, a tripalmitoyl-S-glycerylcysteine modification, is termed Pam3Cys (or is sometimes referred to herein as Pam(3)Cys or Pam3Cys). It has been suggested that the lipid modification allows membrane localization of proteins, with polypeptide portions exposed as immune targets. In addition to serving as targets for the immune response, Pam3Cys-modified proteins, such as OspA, have been reported to act as potent inflammatory stimulants though the toll-like 2 receptor mechanism (TLR2).
The Mayo Clinic advertised the RICO within the RICO – a
patent they were the assignee and would have gotten royalties (6,045,804); CT
AG and now Senator Richard Blumenthal’s staff were interested to know if this
RICO cabal including Yale, Imugen and Corixa ever advertised their intended
monopoly on post-LYMErix blood testing for North America “where the vaccination
status was unknown.” This is one
example. Yale also advertised this new
test:
Can be found at:
https://groups.google.com/forum/#!original/sci.med.diseases.lyme/D6v-QHQdMbc/WupHjKwFilIJ
”http://www.mayo.edu/comm/mcr/news/news_361.html
“Mayo Clinic Rochester News
“ Tuesday, August 4, 1998
“New Tests Set Standard for Diagnosing Lyme Disease
ROCHESTER, MINN. — Mayo Medical Laboratories and IMUGEN Inc. announced today the newest and most accurate test series available for diagnosing Lyme disease. The tests also are the only reliable means of diagnosing Lyme disease in people who have been vaccinated against Lyme disease.
“Mayo Medical Laboratories, the laboratory for Mayo Clinic,
and IMUGEN Inc. of Norwood, Mass., are jointly offering the new proprietary
tests through local hospitals and clinics. Availability of the new tests
coincides with the anticipated release of new Lyme disease vaccines, such as
the widely-publicized LYMErix and ImuLyme.
”In research trials, all other Lyme tests have been shown to produce
false-positive results in people vaccinated against Lyme disease. Moreover, the
downstream costs of medical care delivered on the basis of just one
false-positive Lyme test can be as much as $15,000.
“According to Dr. David Persing, a Mayo Clinic molecular biologist involved in the discovery of the new test components, physicians now have a new and more reliable means of diagnosing patients who present with symptoms of Lyme disease.
"These tests should help reduce the human and financial
costs associated with the number of undiagnosed, misdiagnosed, untreated or
improperly treated patients," Dr. Persing added.
”Scientists at IMUGEN, recognized nationally as the leading reference
laboratory for tick-borne diseases, are responsible for developing the highly
accurate immunologic methods to utilize Dr.Persing’s discovery.
"Diagnosing Lyme disease has been highly problematic for a long time," said Victor Berardi, chief executive officer of IMUGEN, whose laboratories have performed more than a half-million Lyme disease tests. "Our new tests will greatly help physicians in distinguishing patients who are actually infected from those who aren’. Furthermore, the accuracy of these tests will not be affected by Lyme vaccine. In any case, the tests will help physicians render more appropriate and cost effective care."
“Lyme disease is a tick-borne illness that if left undiagnosed or untreated can severely damage the human heart and nervous system. Nationally more than 16,000 cases of Lyme disease were reported to the Centers for Disease Control and Prevention (CDC) in 1996. The majority of cases were reported in New England and the Northeast. The CDC reports that the overall number of Lyme disease cases could climb to 25,710 by the year 2000.
“In a study of 10,936 people in states with a high incidence
of Lyme disease, one new vaccine proved 79 percent effective at preventing Lyme
disease infections after complete dosage. Given the potential popularity of the
vaccine, and the recent epidemic of Lyme disease in the Northeast, the new
tests offered by Mayo Medical Laboratories and IMUGEN will be of considerable
value.
”The new Lyme disease tests detect multiple classes of antibody isotypes,
enabling them to discriminate between the vaccine and a true Lyme infection.
Existing Lyme disease tests, however, have shown to produce false-positive
results in patients vaccinated for Lyme disease.
“IMUGEN Inc. of Norwood, Mass., is a pioneer in the research, development and testing of tick-borne diseases, including Lyme disease, babesiosis and ehrlichiosis. For the past decade, IMUGEN has provided clinics and hospitals in the Northeast with
high-quality serologic testing from its facilities in Norwood, Mass., and Southhampton Hospital in Southhampton, N.Y. For more information, call 781-255-0770.
“Mayo Medical Laboratories is the laboratory for Mayo Clinic and provides lab services to community-based healthcare organizations throughout the nation and world. Mayo Medical
Laboratories draws from the expertise of Mayo Clinic’s 1,600 physicians and scientists who provide specialized consultation on test selection, utilization and interpretation.
“For information, call 800-533-1710.
###
“Contact:
“Tom Huyck
“507-284-0003 (days)
“507-284-2511 (evenings)”
-------------------------
Kathleen Dickson
...